Stoke Therapeutics, Inc. (STOK)

Market Cap	1.08B
Revenue (ttm)	199.89M
Net Income (ttm)	52.49M
Shares Out	54.80M
EPS (ttm)	0.91
PE Ratio	21.76
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	620,344
Open	20.00
Previous Close	19.77
Day's Range	19.36 - 20.00
52-Week Range	5.35 - 20.00
Beta	1.15
Analysts	Strong Buy
Price Target	26.60 (+34.62%)
Earnings Date	Aug 12, 2025

About STOK

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine f...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 19, 2019
• Employees: 128
• Stock Exchange: NASDAQ
• Ticker Symbol: STOK
• Website: https://www.stoketherapeutics.com

Financial Performance

In 2024, Stoke Therapeutics's revenue was $36.56 million, an increase of 316.34% compared to the previous year's $8.78 million. Losses were -$88.98 million, -15.01% less than in 2023.

Analyst Summary

According to 6 analysts, the average rating for STOK stock is "Strong Buy." The 12-month stock price target is $26.6, which is an increase of 34.62% from the latest price.

Price Target

$26.6

(34.62% upside)

Analyst Consensus: Strong Buy